DATA GRAPHICS | Data Byte
Ocrevus remains top MS seller as Kesimpta moves into second place
Sanofi’s Aubagio takes first major hit, while Biogen’s tecfidera continues downward slide
August 1, 2023 10:00 PM UTC
With second quarter earnings in, Roche’s Ocrevus remains the clear market leader in multiple sclerosis, but Novartis’ Kesimpta showed the most growth over 1Q23, narrowly edging out Biogen’s Tysabri for the second-highest sales.
Among eight major MS drugs splitting the portion of the market not obtained by Ocrevus ocrelizumab, only Kesimpta ofatumumab, a CD20 mAb from Novartis AG (SIX:NOVN; NYSE:NVS), is on a positive trajectory. Kesimpta sales grew 27% to $489 million last quarter. ...